A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for Breast Neoplasms
46 locations incl. Hot Springs
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06926868·Phase 2, Phase 3·Recruiting